(Q53003745)

10 May 2018

title

Arthritis induced with cartilage-specific antibodiesis IL-4-dependent. (English)

1 reference

10 May 2018

1 reference

Kutty Selva Nandakumar

series ordinal

1

1 reference

10 May 2018

author name string

Rikard Holmdahl

series ordinal

2

1 reference

10 May 2018

language of work or name

English

0 references

publication date

1 June 2006

1 reference

10 May 2018

European Journal of Immunology

published in

1 reference

10 May 2018

volume

36

1 reference

10 May 2018

issue

6

1 reference

10 May 2018

page(s)

1608-1618

1 reference

10 May 2018

Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex, and genes

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

Redirection of T cell effector function in vivo and enhanced collagen-induced arthritis mediated by an IL-2R beta/IL-4R alpha chimeric cytokine receptor transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

IFN-beta gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Th1/Th2 cytokine balance in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Cytokines and autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

The IL-4 receptor: signaling mechanisms and biologic functions

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Plasmid encoding interleukin-4 in the amelioration of murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

IL-4-deficient mice develop less acute but more chronic relapsing collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Complement activation by both classical and alternative pathways is critical for the effector phase of arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Collagen type II (CII)-specific antibodies induce arthritis in the absence of T or B cells but the arthritis progression is enhanced by CII-reactive T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

The regulation of immunity to Leishmania major

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA)

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Susceptibility to collagen-induced arthritis: cytokine-mediated regulation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Genetic ablation of interferon-gamma up-regulates interleukin-1beta expression and enables the elicitation of collagen-induced arthritis in a nonsusceptible mouse strain

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Paradoxical roles of IFN-gamma in models of Th1-mediated autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Reduced production of interferon alpha and interferon gamma in leukocyte cultures from patients with active rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Interleukin-1 enhances the development of type II collagen-induced arthritis only in susceptible and not in resistant mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Interleukin-4 can be a key positive regulator of inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Genetic influences on the end-stage effector phase of arthritis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Arthritogenic monoclonal antibodies from K/BxN mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Characterization of the antibody response in mice with type II collagen–induced arthritis, using monoclonal anti–type II collagen antibodies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200535633

7 January 2021

Identifiers

DOI

10.1002/EJI.200535633

1 reference

10 May 2018

1 reference

10 May 2018